High purity Pinealon PIN5 PIN10 PIN20 99% Research Peptide Raw Material
2924330-56-1
99%
GuangZhou
LianTuo Technology
5mg*10vials 10mg*10vials 20mg-10vials
2029-01-01
beaty prodt
-
Product Description
-
Seller Information
-
DescriptionSemaglutide is an agonist of glucagon-like peptide 1 receptor (GLP-1R; EC50 = 6.2 pM in a reporter assay using BHK cells expressing the human receptor).1 It decreases blood glucose levels in the db/db mouse model of type 2 diabetes (ED50 = <2 nmol/kg). Semaglutide (25 nmol/kg) prevents decreases in the number of dopaminergic neurons in the substantia nigra and increases in lipid peroxidation in the substantia nigra and striatum, as well as improves motor coordination in the rotarod and footprint tests in a mouse model of Parkinson's disease induced by MPTP.2 It decreases neuronal loss in the hippocampal dentate gyrus and CA1 and CA3 regions and improves motor coordination and grip strength in the beam-walking and hanging wire tests, respectively, in a rat model of stroke induced by permanent middle cerebral artery occlusion (MCAO) when administered at a dose of 10 nmol/kg every other day.3 Formulations containing semaglutide have been used in the treatment of type 2 diabetes.WARNING This product is not for human or veterinary use.Basic Info
-
Product Name:
Semaglutide
Other Name:Semaglutide sodium
CAS No.:2924330-56-1
Molecular Weight:0
Categories:
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
beaty prodt
-
Location:
Room 1664, 3rd Floor, No. 1-2, East Lane, Yuancun Sanheng Road, Tianhe District, Guangzhou City
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
11-50
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product